Purchase Order 75N91020P00174

The National Cancer Institute issued a delivery order to Becton, Dickinson And Company on December 23, 2015, with a ceiling value of $18,559.35 and an ultimate completion date of February 19, 2017. Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis and was issued without a set-aside. Becton, Dickinson And Company, through its BD Biosciences division, supplies flow cytometry instruments, reagents, and consumables essential to biomedical research and...

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson And Company on August 3, 2016, with a ceiling value of $22,701.58 for flow cytometric analysis of benign and malignant tumors.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a time and materials basis and is scheduled for ultimate completion on February 27, 2021.</p>

<p>The National Cancer Institute issued a purchase order to Becton, Dickinson and Company for $3,464.20 on March 24, 2016, for pre-contract inspection and system update services. Place of performance is Bethesda, Maryland. The order was priced on a firm fixed-price basis with an ultimate completion date of February 13, 2021. No small business set-aside was applied.</p>

The National Cancer Institute awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) for a maintenance agreement valued at $21,222.00, with an award date of January 16, 2020 and ultimate completion on January 15, 2021. Place of performance is Bethesda, Maryland. The order is structured as a firm fixed-price purchase order with no set-aside applied. BD Biosciences supplies flow cytometry instrumentation and maintenance services to federal biomedical research and diagnostic...

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on August 17, 2015, with a ceiling value of $10,109.93 for flow cytometric analysis of benign and malignant tumors.</p> <p>Place of performance is Bethesda, Maryland. The order was firm fixed price and ultimately completed on September 18, 2017. No set-aside was used.</p>

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on April 5, 2026, for flow cytometric analysis reagents with a ceiling value of $13,243.25.</p> <p>Place of performance is Bethesda, MD 20892. The order has an ultimate completion date of April 5, 2026, and is priced as firm fixed price. No set-aside was used for this delivery order.</p>

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on November 19, 2015, with a ceiling value of $21,194.00 for flow cytometric analysis of benign and malignant tumors using BD HU CD11B/MAC-1 FITC ICRF44 reagents.</p> <p>Place of performance is Bethesda, MD 20892. The order is firm fixed price with an ultimate completion date of September 18, 2017. No set-aside was used.</p>

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on May 18, 2026, with a ceiling value of $33,250.30 for flow cytometric analysis of benign and malignant tumors reagents.</p> <p>Place of performance is Bethesda, MD 20892. The order is firm fixed price with an ultimate completion date of May 18, 2026. No set-aside was used.</p>

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on July 17, 2015, with a ceiling value of $42,996.78 for flow cytometric analysis reagents and consumables and flow cytometric analysis of benign and malignant tumors.</p> <p>Place of performance is San Jose, CA 95131. The order was to be completed by March 25, 2020. Pricing is firm fixed price. No set-aside was used for this delivery order.</p>

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson And Company on September 18, 2019, with a ceiling value of $62,356.54 for BD Biosciences instrument rental, reagents, quality control material, and instrument supplies.</p> <p>Place of performance is Bethesda, MD 20892. The order carries an ultimate completion date of February 17, 2020. Pricing is firm fixed price, and no set-aside was used for this award.</p>